Raymond James initiated coverage of Perimeter Medical Imaging AI (TSXV:PINK) with an “outperform” rating and price target of $3 (Canadian). The stock closed at $2.19 on Nov. 6. Perimeter is commercializing its Optical...
William Blair launched coverage of Codiak BioSciences (NASDAQ:CDAK) with an “outperform” rating based on the potential of the company’s novel exosome platform and clinical readouts over the next six-to-nine months...
Stifel initiated coverage of AVEO Pharmaceuticals (NASDAQ:AVEO) with a “buy” rating and price target of $9. The stock closed at $5.66 on Nov. 6. AVEO is focused on the development and commercialization of targeted...
SVB Leerink slashed its price target for Neovasc (NASDAQ:NVCN) to $2 from $6, citing timing uncertainty for a U.S. launch of the company’s Reducer stent for percutaneous treatment of refractory angina. The stock closed...
SVB Leerink upgraded Inflarx (NASDAQ:IFRX) to “outperform” from “market perform” and raised its price target to $10 from $7, citing a “significant disconnect between the promise of IFX-1 in multiple applications, most...
H.C. Wainwright upgraded Syros Pharmaceuticals (NASDAQ:SYRS) to “buy” from “neutral” and upped its price target to $15 from $11, saying the company “has turned a corner, in our opinion.” The stock closed at $6.67 on Nov...
Alliance Global Partners raised its price target for Heska (NASDAQ:HSKA) to $163.50 from $116.50 after hosting an investor webcast with the company’s CEO. The stock closed at $116.41 on Nov. 3. Analyst Ben Haynor writes...
SVB Leerink launched coverage of Spruce Biosciences (NASDAQ:SPRB) with an “outperform” rating and $35 price target. The stock closed at $20.30 on Nov. 2 Spruce is a late-stage biotech company developing therapies for...
H.C. Wainwright upgraded STRATA Skin Sciences (NASDAQ:SSKN) to “buy” from “neutral” with a price target of $3. The stock closed at $1.24 on Nov. 2. STRATA is a medical technology company developing and marketing...
Alliance Global Partners initiated coverage of MediPharm Labs (TSX:LABS) with a “buy” rating and price target of $2 (Canadian). The stock was quote at 82 cents around midday on Nov. 2. “We see MediPharm in a position to...
Cowen initiated coverage of Aziyo Biologics (NASDAQ:AZYO) with an “outperform” rating an $20 price target. The stock closed at $10.98 on Oct. 30. Aziyo is a regenerative medicine company that has a three-pronged...
Alliance Global Partners raised its price target for T2 Biosystems (NASDAQ:TTOO) to $1.65 from $1.10 after hosting an investor webcast with the company’s CEO and CFO. The stock closed at $1.34 on Oct. 30. “Our...
H.C. Wainwright reduced its price target for Strongbridge Biopharma (NASDAQ:SBBP) to $10 from $18, citing an analysis of the changing dynamics of the Cushing’s syndrome landscape because of competitor programs. The...
Chardan Capital Markets launched coverage of DURECT (NASDAQ:DRRX) with a “buy” rating and price target of $7. The stock closed at $1.76 on Oct. 29. “We expect that DURECT’s lead pipeline asset, DUR-928, will...
William Blair launched coverage of Aspira Women’s Health (NASDAQ:AWH) with an “outperform” rating. The stock closed at $3.63 on Oct. 29. The company’s current product line, the OVA family, is used for presurgical pelvic...
William Blair initiated coverage of DermTech (NASDAQ:DMTK) with an “outperform” rating. The stock closed at $11.75 on Oct. 29. Analyst Brian Weinstein writes that DermTech is focused on driving adoption of its non...
Chardan Capital Markets initiated coverage of Axcella Health (NASDAQ:AXLA) with a “buy” rating and $16 price target. The stock closed at $4.45 on Oct. 26 “We expect that Axcella’s pipeline of endogenous metabolic...
William Blair launched coverage of Silence Therapeutics (NASDAQ:SLN) with an “outperform” rating and fair value estimate of $31. The stock closed at $15.50 on Oct. 26. Silence Therapeutics is developing a GalNAc...
H.C. Wainwright downgraded Catabasis Pharmaceuticals (NASDAQ:CATB) to “neutral” from “buy” and removed its price target after the company announced that the Phase 3 PolarisDMD trial testing edasalonexent in 131 patients...
Ladenburg Thalmann initiated coverage of Immunome (NASDAQ:IMNM) with a “buy” rating and price target of $28. The stock closed at $11.74 on Oct. 23. Immunome is using its Immunome Discovery Engine (IDE) platform to...
SVB Leerink launched coverage of Athenex (NASDAQ:ATNX) with an “outperform” rating and $22 price target. The stock closed at $11.45 on Oct. 23. Analyst Jonathan Chang, Ph.D., writes that Athenex has leveraged its...
Mackie Research Capital initiated coverage of CB2 Insights (CSE:CBII) with a “speculative buy” rating and price target of $1.10. The stock closed at 59 cents on Oct. 23. CB2 Insights is a health care services and...